Table 1 Sociodemographic and clinical characteristics (N = 106)
Factor | Frequency (%) |
|---|---|
Age (years) | |
< 45 | 32 (30.2) |
45–65 | 57 (53.8) |
> 65 | 17 (16.0) |
Body mass index | |
< 18.5 | 2 (1.9) |
18.5–24.9 | 25 (23.6) |
25–29.9 | 37 (34.9) |
≥ 30 | 42 (39.6) |
Residency | |
City | 53 (50.0) |
Village | 45 (42.5) |
Camp | 8 (7.5) |
Smoking | |
No | 89 (84.0) |
Yes | 17 (16.0) |
University qualification | |
No | 71 (67.0) |
Yes | 35 (33.0) |
Work | |
Unemployed | 89 (84.0) |
Employed | 17 (16.0) |
Material status | |
Single | 23 (21.7) |
Married | 83 (78.3) |
Family history | |
No | 46 (43.4) |
Yes | 60 (56.6) |
Comorbidities | |
No | 51 (48.1) |
Yes | 55 (51.9) |
Chronic medication | |
No | 33 (31.1) |
Yes | 73 (68.9) |
Number of clinic visits per year | |
< 12 | 29 (27.4) |
≥ 12 | 77 (72.6) |
Hospitalized in the last year | |
No | 69 (65.1) |
Yes | 37 (34.9) |
Pathology type | |
Lobular | 8 (7.6) |
Ductal | 93 (87.7) |
None | 4 (3.8) |
Both | 1 (0.9) |
Breast surgery | |
No | 20 (18.9) |
Yes | 86 (81.1) |
Radiotherapy | |
No | 37 (34.9) |
Yes | 69 (65.1) |
Chemotherapy | |
No | 21 (19.8) |
Yes | 85 (80.2) |
Biological therapy | |
No | 86 (81.1) |
Yes | 20 (18.9) |
Targeted therapy | |
No | 86 (81.1) |
Yes | 20 (18.9) |
Initial hormonal therapy | |
Tamoxifen | 50 (47.2) |
Exemestane | 11 (10.4) |
Letrozole | 33 (31.1) |
Anastrozole | 12 (11.3) |
Current hormonal therapy | |
Tamoxifen | 33 (31.1) |
Exemestane | 18 (17.0) |
Letrozole | 41 (38.7) |
Anastrozole | 14 (13.2) |
Hormonal drug switching | |
No | 76 (71.7) |
Yes | 30 (28.3) |
Duration of starting current hormonal therapy | |
< 1 year | 36 (34.0) |
≥ 1 year | 70 (66.0) |
HER2 status | |
Negative | 82 (77.4) |
Positive | 24 (22.6) |
Disease recurrence | |
No | 95 (89.6) |
Yes | 11 (10.4) |
Menopausal status | |
Premenopause | 56 (52.8) |
Postmenopause | 50 (47.2) |